



Oregon Health & Science University  
Hospital and Clinics Provider's Orders

PO7071



ADULT AMBULATORY INFUSION ORDER  
**Eculizumab Infusion**

Page 1 of 4

ACCOUNT NO.  
MED. REC. NO.  
NAME  
BIRTHDATE

*Patient Identification*

**ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.**

Weight: \_\_\_\_\_ kg      Height: \_\_\_\_\_ cm

Allergies: \_\_\_\_\_

Diagnosis Code: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_ Patient to follow up with provider on date: \_\_\_\_\_

**\*\*This plan will expire after 365 days at which time a new order will need to be placed\*\***

**GUIDELINES FOR ORDERING**

1. Send **FACE SHEET and H&P or most recent chart note.**
2. Eculizumab and eculizumab biosimilars are part of **FDA REMS** Program(s). Note that the REMS program for eculizumab-aagh (Epysqli) is separate from that of eculizumab (Soliris) and requires separate enrollment.
  - a. Providers **MUST** be enrolled in the appropriate REMS. **A Provider Prescriber Enrollment ID MUST BE FILLED OUT:** \_\_\_\_\_
  - b. Provide patient with both the Patient Safety Brochure and Patient Safety Card. Patient should carry the card with them at all times.
  - c. Please see reference the respective REMs program websites for the enrollment form(s) and additional help
3. Patients must receive the following meningococcal vaccine at least 2 weeks prior to treatment initiation:
  - a. Meningococcal serogroups A, C, W, Y vaccine (MenACWY) -Menveo, Menactra, or MenQuadfi. These require booster shots every 5 years.  
Date of last vaccination: \_\_\_\_\_
  - b. Meningococcal serogroup B vaccine -Bexsero or Trumenba. These require booster shots 1 year after primary series and every 2 to 3 years thereafter.  
Date of last vaccination: \_\_\_\_\_
  - c. Meningococcal serogroup A, B, C, W, Y vaccine – Penbraya, Penmenvy. Penbraya is approved as an alternative to separate administration of MenACWY and MenB when both would have been given in clinic on the same day persons aged ≥10 years who are at increased risk for meningococcal disease. Penbraya and Penmenvy are not utilized for booster doses. Booster requirement defaults to individual serogroup vaccines and recommendations as detailed above.  
Date of last vaccination: \_\_\_\_\_

Documentation for vaccines must be sent with the order.

Patients not vaccinated should be on prophylaxis antibiotics until vaccines are up to date. Patients who have been vaccinated less than 2 weeks prior to start of infusion should be on 2 weeks of antibacterial prophylaxis.

**Prescriber must update the status of the patient's meningococcal vaccination, indication, and antibacterial drug prophylaxis into the respective online portal.**

**Has this been done? (Yes) (No) – Circle One**

**If no, you must document the one-time status into the online portal before you may treat the patient.**

4. Treatment should be administered at the recommended time interval although administration may vary by ±2 days.



Oregon Health & Science University  
Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER  
**Eculizumab Infusion**

Page 2 of 4

ACCOUNT NO.  
MED. REC. NO.  
NAME  
BIRTHDATE

*Patient Identification*

**ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( ✓ ) TO BE ACTIVE.**

5. Monitoring during therapy: monitor platelet count, serum LDH levels, and serum creatinine levels during therapy. Monitor for signs and symptoms of infection, in particular meningococcal infections.
6. Monitoring after discontinuation:
  - a. Atypical hemolytic uremic syndrome (aHUS) patients who discontinue treatment should be monitored closely for at least 12 weeks for signs and symptoms of thrombotic microangiopathy (TMA) complications.
  - b. Paroxysmal nocturnal hemoglobinuria (PNH) patients who discontinue treatment should be monitored for at least 8 weeks for signs and symptoms of hemolysis
7. Consider penicillin prophylaxis for the duration of eculizumab therapy to potentially reduce the risk of meningococcal disease.

**PRE-SCREENING: (Must be available prior to initiation of therapy):**

- Meningococcal serogroups A, C, W, Y vaccine (MenACWY) -MenQuadfi, Menactra, or Menveo given on (dates) \_\_\_\_\_
- Meningococcal serogroup B vaccine -Bexsero or Trumenba given on (dates) \_\_\_\_\_
- Meningococcal serogroup A, B, C, W, Y vaccine – Penbraya or Penmenvy given on (dates) \_\_\_\_\_

**LABS:**

- CBC with differential, Routine, ONCE, every \_\_\_\_\_ (visit)(days)(weeks)(months) – *Circle One*
- CMP, Routine, ONCE, every \_\_\_\_\_ (visit)(days)(weeks)(months) – *Circle One*
- LDH TOTAL, Routine, ONCE every \_\_\_\_\_ (visit)(days)(weeks)(months) – *Circle One*
- Labs already drawn. Date: \_\_\_\_\_

**NURSING ORDERS:**

1. Vital signs at baseline, post-infusion, and prior to discharge.
2. Monitor for 1 hour after infusion complete for signs or symptoms of infusion reaction. May discontinue observation if stable and tolerating infusions.
3. Hold treatment and notify provider if patient is not up to date on meningococcal vaccination every 5 years for MenACWY (Menveo, Menactra, or MenQuadfi) or 1 year after primary series and every 2 to 3 years thereafter for MenB (either Bexsero or Trumenba).
4. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.



Oregon Health & Science University  
Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER  
**Eculizumab Infusion**

Page 3 of 4

ACCOUNT NO.  
MED. REC. NO.  
NAME  
BIRTHDATE

*Patient Identification*

**ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( ✓ ) TO BE ACTIVE.**

**Biosimilar selection (must check one) – applies to all orders below**

- SOLIRIS (eculizumab)
- EPYSQLI (eculizumab-aagh)
- \_\_\_\_\_

At OHSU clinics, if insurance requires a different biosimilar agent, pharmacy will update the order per CDTM.

- Only check this box if it is NOT okay to substitute for insurance. Dispense as written (DAW).

**MEDICATIONS:**

**Atypical hemolytic uremic syndrome (aHUS), Generalized myasthenia gravis, refractory, or Neuromyelitis optica spectrum disorder**

- Initial doses:** 900 mg in sodium chloride 0.9% 90 mL, intravenous, ONCE, Weekly x 4 doses
- Maintenance doses:** 1200 mg in sodium chloride 0.9% 120 mL, intravenous, ONCE, Every 2 weeks x \_\_\_\_\_ doses, begin on week 5

Infuse over 35 minutes. Infusion may be slowed or stopped due to adverse reactions but should be finished within 2 hours

Provide patient with Patient Safety Card to keep at all times.

**Paroxysmal nocturnal hemoglobinuria (PNH)**

- Initial doses:** 600 mg in sodium chloride 0.9% 60 mL, intravenous, ONCE, Weekly x 4 doses
- Maintenance doses:** 900 mg in sodium chloride 0.9% 90 mL, intravenous, ONCE, Every 2 weeks x \_\_\_\_\_ doses, begin on week 5

Infuse over 35 minutes. Infusion may be slowed or stopped due to adverse reactions but should be finished within 2 hours

Provide patient with Patient Safety Card to keep at all times

**HYPERSENSITIVITY MEDICATIONS:**

1. NURSING COMMUNICATION – If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
2. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
3. EPINEPHrine HCl (ADRENALIN) injection, 0.5 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction



Oregon Health & Science University  
Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER

**Eculizumab Infusion**

Page 4 of 4

ACCOUNT NO.  
MED. REC. NO.  
NAME  
BIRTHDATE

*Patient Identification*

**ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( ✓ ) TO BE ACTIVE.**

**By signing below, I represent the following:**

I am responsible for the care of the patient (*who is identified at the top of this form*);

I hold an active, unrestricted license to practice medicine in:  Oregon  \_\_\_\_\_ (*check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon*);

**My physician license Number is # \_\_\_\_\_ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION);** and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

**Provider signature:** \_\_\_\_\_ **Date/Time:** \_\_\_\_\_

**Printed Name:** \_\_\_\_\_ **Phone:** \_\_\_\_\_ **Fax:** \_\_\_\_\_

Central Intake:

Phone: 971-262-9645 (providers only) Fax: 503-346-8058

**Please check the appropriate box for the patient's preferred clinic location:**

**Beaverton**

OHSU Knight Cancer Institute  
15700 SW Greystone Court  
Beaverton, OR 97006  
Phone number: 971-262-9000  
Fax number: 503-346-8058

**NW Portland**

Legacy Good Samaritan campus  
Medical Office Building 3, Suite 150  
1130 NW 22nd Ave  
Portland, OR 97210  
Phone number: 971-262-9600  
Fax number: 503-346-8058

**Gresham**

Legacy Mount Hood campus  
Medical Office Building 3, Suite 140  
24988 SE Stark  
Gresham, OR 97030  
Phone number: 971-262-9500  
Fax number: 503-346-8058

**Tualatin**

Legacy Meridian Park campus  
Medical Office Building 2, Suite 140  
19260 SW 65th Ave  
Tualatin, OR 97062  
Phone number: 971-262-9700  
Fax number: 503-346-8058

Infusion orders located at: [www.ohsuknight.com/infusionorders](http://www.ohsuknight.com/infusionorders)